Want to see NEUP full AI Analyst Report?

Neuphoria Therapeutics (NEUP) Price & Analysis

301 Followers

NEUP Stock Chart & Stats

$4.64

-$0.37(-10.36%)

At close: Jan 08 4:00 PM EST

$4.64

-$0.37(-10.36%)

Day’s Range― - ―

52-Week Range$3.19 - $21.40

Previous CloseN/A

Volume31.57K

Average Volume (3M)89.21K

Market Cap

$20.97M

Enterprise Value$3.89M

Total Cash (Recent Filing)$19.44M

Total Debt (Recent Filing)$34.23K

Price to Earnings (P/E)―

Beta1.71

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding5,404,551

10 Day Avg. Volume91,705

30 Day Avg. Volume89,214

Financial Highlights & Ratios

PEG Ratio-0.24

Price to Book (P/B)0.40

Price to Sales (P/S)0.74

P/FCF Ratio0.15

Enterprise Value/Market Cap0.19

Enterprise Value/Revenue-0.37

Enterprise Value/Gross Profit-0.35

Enterprise Value/Ebitda-0.20

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low LeverageNear-zero debt is a durable strength for a clinical-stage biotech: it reduces refinancing and solvency risk during long development cycles, preserves optionality for milestone-linked investments, and gives management flexibility to fund trials or negotiate deals without immediate pressure from creditors.

Recent Cash GenerationSustained positive operating and free cash flow in the latest periods creates a real funding runway for development activities and reduces near-term dilution risk. For a biotech, ability to generate cash internally supports funding of R&D and licensor obligations without sole reliance on equity markets.

Merger And Financing PackageA strategic merger combined with a structured financing package is a structural change: it aligns capital to fund a registrational Phase 3, increases scale and geographic listing profile, and materially extends projected runway—improving long-term development visibility if approvals and conditions are met.

Bears Say

Large TTM Loss And Revenue FallA massive trailing-twelve-month loss and revenue deterioration are structural red flags: persistent sizeable operating deficits erode capital, weaken negotiating leverage with partners, and can force repeated financings or program reprioritization, threatening long-term value creation.

Cashflow VolatilityIntermittent cash generation undermines planning for multi-year trials: volatile cash flows increase financing uncertainty, raise the probability of disruptive equity or debt raises, and make long-term R&D commitments harder to fund predictably without contingent or transactional funding sources.

Eroding Equity And Negative ROEDeclining shareholders' equity and strongly negative ROE indicate erosion of the balance sheet buffer: continued losses shrink capital available for operations, constrain borrowing capacity, and increase the likelihood of dilutive financing, limiting long-term shareholder value retention.

Neuphoria Therapeutics News

Neuphoria Therapeutics to be acquired by Scancell

Neuphoria Therapeutics (NEUP) and Scancell Holdings announced an all-share merger in which Scancell will acquire Neuphoria. Upon completion...

15d ago

NEUP

Neuphoria Therapeutics to Merge with Scancell Holdings

Neuphoria Therapeutics ( ($NEUP) ) has provided an announcement. On July 23, 2026, Neuphoria Therapeutics agreed to an...

14d ago

NEUP

Neuphoria Therapeutics confirms merger discussions with Scancell Holdings

Neuphoria Therapeutics (NEUP) issued the following statement in response to an announcement made by London-listed biotechnology company Scancell...

1M ago

NEUP

Neuphoria Receives Milestone Revenue From Pfizer KAT6 Trial

The latest update is out from Neuphoria Therapeutics ( ($NEUP) ). On May 21, 2026, Neuphoria Therapeutics received...

2M ago

NEUP

Neuphoria Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis downgraded Neuphoria Therapeutics (NEUP) to Neutral from Buy with no price target after...

3M ago

NEUP

Neuphoria Therapeutics Announces CEO Transition and Consulting Role

Neuphoria Therapeutics ( ($NEUP) ) has issued an update. Neuphoria Therapeutics Inc. announced that Spyridon “Spyros” Papapetropoulos, M.D.,...

7M ago

NEUP

Neuphoria Therapeutics Shareholders Align on Key Proposals

Neuphoria Therapeutics ( ($NEUP) ) has shared an update. On December 12, 2025, Neuphoria Therapeutics held its Annual...

8M ago

NEUP

Neuphoria announces ISS recommends shareholders vote ‘FOR’ director nominees

Neuphoria Therapeutics (NEUP) announced that Institutional Shareholders Services, ISS, a leading independent proxy advisory firm, has issued a...

8M ago

NEUP

Neuphoria Therapeutics price target lowered to $7 from $21 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Neuphoria Therapeutics (NEUP) to $7 from $21 and keeps a...

8M ago

NEUP

Neuphoria Therapeutics responds to Lynx1’s revised indication of interest

Neuphoria Therapeutics (NEUP) issued the following statement in response to dissident stockholder, Lynx1 Master Fund’s, revised indication of...

8M ago

NEUP

Neuphoria Therapeutics ‘exposes false narratives’ responding to Lynx1

The company states: “Neuphoria Therapeutics (NEUP) issued the following statements to address what Neuphoria strongly believes is a...

8M ago

NEUP

Neuphoria Therapeutics urges stockholders to vote for company nominees

Neuphoria Therapeutics (NEUP) issued a letter to its stockholders regarding Neuphoria’s 2025 Annual Meeting of Stockholders, which is...

9M ago

NEUP

Neuphoria initiates strategic review, confirms receipt of indication of interest

Neuphoria Therapeutic announced, as previously disclosed, the initiation of a review of strategic alternatives to advance the Company’s...

9M ago

NEUP

Neuphoria Therapeutics Declares Dividend Rights Plan

Neuphoria Therapeutics ( ($NEUP) ) has shared an announcement. On October 25, 2025, Neuphoria Therapeutics‘ Board of Directors...

9M ago

NEUP

NEUP FAQ

What was Neuphoria Therapeutics’s price range in the past 12 months?

Neuphoria Therapeutics lowest stock price was $3.19 and its highest was $21.40 in the past 12 months.

What is Neuphoria Therapeutics’s market cap?

Neuphoria Therapeutics’s market cap is $20.97M.

When is Neuphoria Therapeutics’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Neuphoria Therapeutics’s earnings last quarter?

Currently, no data Available

Is Neuphoria Therapeutics overvalued?

According to Wall Street analysts Neuphoria Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Neuphoria Therapeutics pay dividends?

Neuphoria Therapeutics does not currently pay dividends.

What is Neuphoria Therapeutics’s EPS estimate?

Neuphoria Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Neuphoria Therapeutics have?

Neuphoria Therapeutics has 5,404,551 shares outstanding.

What happened to Neuphoria Therapeutics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Neuphoria Therapeutics?

Currently, no hedge funds are holding shares in NEUP

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Neuphoria Therapeutics

Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials. Its core mission involves pioneering therapies specifically engineered to address the intricate requirements of individuals living with neuropsychiatric disorders. The company was established on December 23, 2024, and its main corporate offices are located in Burlington, Massachusetts.

Neuphoria Therapeutics (NEUP) Earnings & Revenues

Historic Earnings Reports

NEUP Stock 12 Month Forecast

Average Price Target

―

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"NaN":"―"}},"plotLines":[{"color":"rgba(0,0,0,0)","label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[null,null,null,null,null],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.88,3.5815384615384613,3.283076923076923,2.9846153846153847,2.686153846153846,2.3876923076923076,2.0892307692307694,1.790769230769231,1.4923076923076923,1.1938461538461538,0.8953846153846152,0.5969230769230771,0.29846153846153856,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.05,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.95,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.85,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.55,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.39,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.88,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.04,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.26,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.12,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.22,"date":1777593600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.3,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.55,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.88,"date":1785542400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >